Compliance with Antimicrobial Therapy for Buruli Ulcer | Zendy

Sandor-Adrian Klis | Zendy; Riemer Adam Kingma | Zendy; Wilson Tuah | Zendy; Ymkje Stienstra | Zendy; Tjip S. van der Werf | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Compliance with Antimicrobial Therapy for Buruli Ulcer

Author(s) -

Sandor-Adrian Klis,

Riemer Adam Kingma,

Wilson Tuah,

Ymkje Stienstra,

Tjip S. van der Werf

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.03763-14

Subject(s) - buruli ulcer , antimicrobial , medicine , compliance (psychology) , microbiology and biotechnology , intensive care medicine , biology , disease , psychology , social psychology

We read with great interest the study by Philips et al. ([1][1]) reporting on successful outcomes of the combination of streptomycin and rifampin for 2 weeks, followed by clarithromycin and rifampin for 6 weeks, in the treatment of Buruli ulcer (BU). Currently, drug treatment for BU consists of 8

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research